Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...

Pfizer's adjusted EPS of $0.63 surpassed the expected $0.47 ... Paxlovid sales came in at $727 million compared to a $3.14 ...

Pfizer (PFE) reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations ...

Since the beginning of 2024, PFE stock has underperformed the S&P 500 index, delivering -3% returns compared to the index’s ...

Q4 2024 Earnings Call Feb 04, 2025, 10:30 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants.

Pfizer’s PFE fourth-quarter results were strong as it beat estimates for earnings as well as sales. Adjusted earnings per share of 63 cents were much higher than 10 cents in the year-ago ...

Pfizer (PFE) stock is up today after the pharmaceutical company reported earnings for the fourth quarter of 2024. The company ...

Pfizer Inc (PFE) reports robust financial performance with significant revenue growth and strategic progress in oncology and ...

After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.”  | The company benefited from higher-than-expected sales of ...

Pfizer faces stagnant revenue and patent cliffs. Learn why I downgraded PFE stock to Strong Sell despite a 24.7% YoY growth ...

Analysts expect the New York-based company to report quarterly earnings at 46 cents per share, up from 10 cents per share in ...